NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license agreements with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to generate and validate novel antibody-drug conjugate (ADC) therapies using monoclonal antibodies […]
Yearly Archives: 2022
4 posts
NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic biologics for the treatment of advanced and metastatic cancers, today announced a multitarget research and development collaboration and license option agreement with Binghamton University. The collaboration will utilize novel […]
Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer NEW YORK, NY, March 23, 2022 /24-7PressRelease/ — Manhattan BioSolutions, Inc, an emerging biotechnology company developing a new class of targeted immunotherapies for the treatment of advanced and metastatic cancers, has been awarded […]
Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for the treatment of advanced and metastatic cancers, has been awarded grant funding as part of Round 3 of the New Jersey Commission on Science, Innovation, and Technology Direct Financial […]